Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an
unmet need for treatments that provide rapid and high levels of skin clearance and itch …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Abstract Background The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces
interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic …

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent
eczematous lesions and intense itch. Although it most often starts in infancy and affects …

Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …